endogenous analgesic opioid peptides, has been isolated from bovine brain by means of a sensitive analgesic method and reported to release Met-enkephalin (1) . Recent electro physiological studies, however, suggest that KTP acts on rat cerebral neurons through two different mechanisms: an enkephalin releasing mechanism and a mechanism without involvement of enkephalin (2) .
Immunological mediator release from rat mast cells is modulated by various neuroactive substances. By their effects on this immuno logical release, rat mast cells have been found to contain several types of phar macological receptors including muscarinic (3), adenosine (4), PGE, (3, 5, 6) , PGI2 (7) and opioid receptors (5, 6) . The fact that rat mast cells contain opioid receptors, taken together with the possibility that KTP may act on neurons directly as well as indirectly, prompted us to examine the effect of KTP on IgE-mediated 14C-serotonin release from rat mast cells.
Serosal mast cells from 5 rats of the Wistar strain (180-220 g) in each experiment were incubated at 37°C for 60 min in a 5-fold dilution of anti-ovalbumin IgE-rich serum of immunized BALB/c mice, containing 4 ,ug 14C-serotonin (0 .1 uCi/,ug). After washing three times with mast cell medium (MCM: 154 mM NaCI, 2.7 mM KCI, 0.9 mM CaCI2, 0.45 mM MgCl2, 10% (V/V) Sorensen phosphate buffer (pH 7.0), 0.1% (W/V) gelatin and 0.1% (W/V) glucose), im munological activation of mast cells with ovalbumin (final concentration of 2 ,ug/ml) was carried out in MCM containing 5 tiM serotonin, following preincubation at 37°C for 6 min with KTP, opiates, PGE, or a combination of KTP, opiates and PGE1. Naloxone was added 2 min before pre incubation. Antigen-induced 14C-serotonin release from rat mast cells was stopped 1 min after the antigen challenge by the formal dehyde method (5, 6) . By this time, over 90% of the release reaction was completed (5, 6) . After centrifugation, aliquots of the supernatant and pellet were taken for the determination of radioactivity with a liquid scintillation spectrometer. Reagents and their sources were as follows: Ovalbumin (Grade V), prostaglandin E1, serotonin creatinine sulfate from the Sigma Chemical Company; levorphanol tartrate and dextrorphan tartrate from Hoffman LaRoche; naloxone hydro chloride from Endo Laboratories Inc.; mor phine hydrochloride from the Sankyo Co.; (side chain 2-14C-)5-hydroxytryptamine creatinine sulfate (58 mCi/mmol) from New England Nuclear. Net antigen-induced release of 14C-serotonin, corrected for spontaneous release from control cells, was expressed as percent of 14C-serotonin release.
Various pharmacological agents are known to modulate mediator release from rat mast cells. In general, an increase in the level of cellular cyclic AMP in these cells supresses and a decrease enhances mediator release (3). Stimulation of muscarinic receptors lowers the mast cell cyclic AMP content and thus potentiates compound 48/80-induced hista mine release (3). Since mammalian cerebral neurons show excitatory response to ion tophoretically applied acetylcholine through muscarinic receptors (8) as well as to KTP applied in the same way (2), we examined the effect of KTP on IgE-mediated 14C serotonin release from rat mast cells. As shown in Fig. 1 Net antigen-induced 14C serotonin release was 23.5±4.5% (n=8), while spontaneous release was 4.5±0.5% (n=8) 1 min after antigen challenge.
The degree of inhibition achieved with 2 X 10-6 M PGE, was 35.5±4.0% (n=8).
A, morphine; B, levorphanol; C, dextrorphan; D, KTP; MOR, morphine; LEV, levorphanol; NAL, naloxone. mediated 14C-serotonin release in a dose related manner and morphine (3X10-7_ 3x10-5 M) dose-dependently reverses this inhibitory response of mast cells to 2 X 10-6 M PGE1. Moreover, this anti-PGE, action of morphine was antagonized by naloxone which itself did not affect the inhibition by 2X10'6 M PGE1 of this immunological reaction. In addition, the reversal by morphine of 2x10-6 M PG E1-induced inhibition of mediator release could be mimicked by levorphanol (3X10-8-10'6 M), a congener of morphine, dose-dependently; but dex trorphan, an enatiomer of levorphanol, did not reverse this PGE1 effect at concen trations up to 10-4 M. These observations suggest that rat mast cells contain opioid receptors (5, 6) . All these observations were also confirmed in the present studies (Fig. 2) . Since rat mast cells may contain opioid receptors, we also examined the interaction of 2x10-6 M PG E1 and various concen trations of KTP on these cells by their effect on this release reaction. In contrast to the opiates, KTP did not show such anti-PGE1 action at concentrations of 10-7 M to 10-4 M (Fig. 2) . With respect to IgE-mediated 14C serotonin release itself, morphine (3 x 10-5 M), naloxone (2x 10-4 M), levorphanol (10-6 M) and dextrorphan (10-4 M) caused no changes (not shown).
Thus, we could not demonstrate that rat mast cells have an active site for KTP despite the presence of the opioid receptors as demonstrated in rat brain homogenates (1).
In conclusion, KTP does not modulate IgE-mediated 14C-serotonin release from rat mast cells. 
